29 June 2023 in Medical alphabet
Hypofractionated radiotherapy in the treatment of breast cancer patients has a signifiant advantage over conventional fractionation due to the shorter duration of treatment course while maintaining its antitumor effiacy. Usage of hypofractionated regimens may be restricted in patients with immediate breast reconstruction because of higher rate of complications. The aim of this study is to evaluate the incidence of complications in the reconstructed breast after hypofractionated radiotherapy. The study involved 100 patients with breast cancer after immediate implant-based breast reconstruction who underwent an adjuvant course of external beam radiation therapy with a single dose of 2.67 Gy to a total dose of 40.05 Gy. In our study the incidence of capsular contracture is 8 %, infectious complications – 2.3 %, protrusion – 4.6 %. The total incidence of complications is 15 %, which does not exceed the incidence in conventional fractionation.
31 December 2020 in Journal of oncology: diagnostic radiology and radiotherapy
Лучевая терапия в комплексном лечении больных мезотелиомой плевры
6 December 2022 in Meditsinskiy sovet = Medical Council
For patients with the metastatic subtype of luminal HER-2-negative (HR+/HER2-) breast cancer (mBC) in the absence of visceral crisis, the gold standard of treatment is a combination of CDK4/6 inhibitors and aromatase inhibitors, regardless of their menopausal status and the sites of metastasis. The effectiveness of this approach was confirmed in the MONARCH, PALOMA, MONALEESA study cycles for the drugs abemaciclib, palbociclib and ribociclib, respectively. Metastasis in the central nervous system (CNS) in breast cancer complicates the treatment of patients and leads to the search for new approaches to the choice of therapy. To date, neurosurgical and radiosurgical techniques are actively used, however, drug therapy still stands for the leading positions. Data on the use of CDK4/6 inhibitors or aromatase inhibitors in patients with CNS metastases are limited. Most studies did not include patients with CNS metastases, only PALOMA-2,3 and MONALEESA-3 studies allowed the inclusion of patients with either “inactive” CNS metastases or after exposure to local treatment methods (for example, radiosurgery, radiotherapy, or surgery). In the study of real clinical practice of combined endocrine therapy with ribociclib (CompLEEment-1) allowed the inclusion of patients with active brain metastases (n = 51), while the subgroup analysis demonstrated the benefits of using a combination of ribociclib and aromatase inhibitors in patients in this difficult clinical situation. In the article, the authors review the available data from randomized clinical trials and real clinical practice, and also illustrate with their own observation.
21 December 2020 in Meditsinskiy sovet = Medical Council
Introduction. Nowadays the stereotactic radiotherapy (SRT) of patients with clinical stage I-II lung cancer is the choice of the treatment modality for functionally inoperable patients. It shows safety and high efficiency in reaching the local control. Though there is a range of unsolved issues connected with the prediction of treatment efficiency and frequency of complications, an integration of new technologies in the planning and treatment process allows to widen the search of the predictive factors.Materials and methods. Since 2014, 42 patients (T1N0M0 – 16 patients, T2N0M0 – 26 patients) with clinical stage I-IIa lung cancer have underwent SRT. The majority of patients (38) have been recognized as functionally inoperable due to the concurrent broncho-pulmonary pathology, 4 conditionally operable patients have refused an operation. 11 patients had the primary multiple tumors in their anamneses, 3 patients had a сentral tumor. Used dose fractionation options were: 10 Gy х 5 fractions (n = 29) and 7 Gy х 8 fractions (n = 13) – BED = 100 Gy.Resuts. The median follow-up was 32 months (range 6–56 months). The 3-year local control was 94%. The isolated local recurrences were not registered. Overall 3-year survival rate was 74% (95% CI, 60–90) and a 3-year tumor-specific survival rate – 84% (95% CI, 71–98). During one-factor analysis a reliable influence on the prognosis of the fractionation regimen (р = 0,04) and, close to reliability, the initial SUVmax level influence (р = 0,07) were revealed. Grade 3 pulmonary toxicity was observed in 4 (9%) patients, one patient with a Central tumor died from pulmonary hemorrhage (grade 5 toxicity). Grade 3 chest pain was observed in 3 (7%) patients, two of them had a rib fracture.Conclusions. With modern approaches to SRT treatment planning and delivery there should be a search for additional treatment efficiency and toxicity predictors. The total dose delivery regimen and initial tumor SUVmax can be predictive efficiency factors, while the pulmonary tissue volume can be a predictive toxicity factor.
21 June 2023 in Journal of oncology: diagnostic radiology and radiotherapy
Radiation therapy of the primary tumor can be a stage of treatment of patients with initial IV stage breast cancer, being delievered out not only in purpose of decreasing symptom’s severity, but with an increase of progression-free survival.Modern technologies of radiation therapy, including intensity-modulated radiotherapy and radiation therapy with deep inspiration under the control of breathing (Respiratory Gating), can significantly reduce dose to risk organs and ensure a homogeneous isodose distribution in the irradiated area, which is especially important in patients receiving systemic treatment, which in itself has clinically significant cardio- and pulmonotoxicity.The presented clinical case demonstrates the possibility of dose reduction to organs at risk with usage of modern technologies of conformal radiation therapy.
19 June 2020 in Journal of oncology: diagnostic radiology and radiotherapy
Лучевая терапия плоскоклеточного рака анального канала: поиски оптимальных решений